BR112022017530A2 - Derivado de oxadiazol - Google Patents
Derivado de oxadiazolInfo
- Publication number
- BR112022017530A2 BR112022017530A2 BR112022017530A BR112022017530A BR112022017530A2 BR 112022017530 A2 BR112022017530 A2 BR 112022017530A2 BR 112022017530 A BR112022017530 A BR 112022017530A BR 112022017530 A BR112022017530 A BR 112022017530A BR 112022017530 A2 BR112022017530 A2 BR 112022017530A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxadiazole derivative
- formula
- relates
- present
- epilepsy
- Prior art date
Links
- 150000004866 oxadiazoles Chemical class 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020046138 | 2020-03-17 | ||
| PCT/JP2021/010628 WO2021187486A1 (ja) | 2020-03-17 | 2021-03-16 | オキサジアゾール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017530A2 true BR112022017530A2 (pt) | 2022-10-18 |
Family
ID=77768228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017530A BR112022017530A2 (pt) | 2020-03-17 | 2021-03-16 | Derivado de oxadiazol |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20230265061A1 (https=) |
| EP (1) | EP4122923B1 (https=) |
| JP (2) | JP7637121B2 (https=) |
| KR (1) | KR20220154208A (https=) |
| CN (1) | CN115515943B (https=) |
| AU (1) | AU2021239631A1 (https=) |
| BR (1) | BR112022017530A2 (https=) |
| CA (1) | CA3170273A1 (https=) |
| DK (1) | DK4122923T3 (https=) |
| ES (1) | ES3041051T3 (https=) |
| FI (1) | FI4122923T3 (https=) |
| MX (1) | MX2022011483A (https=) |
| PH (1) | PH12022552373A1 (https=) |
| PT (1) | PT4122923T (https=) |
| TW (1) | TWI879917B (https=) |
| WO (1) | WO2021187486A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4122923T3 (da) * | 2020-03-17 | 2025-12-15 | Sumitomo Pharma Co Ltd | Oxadiazolderivat |
| JP7653399B2 (ja) | 2021-09-22 | 2025-03-28 | 住友ファーマ株式会社 | オキサジアゾール誘導体を含有する医薬組成物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1227978A (https=) * | 1968-09-13 | 1971-04-15 | ||
| TW200715993A (en) | 2005-06-15 | 2007-05-01 | Senomyx Inc | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers |
| JP5015172B2 (ja) * | 2005-12-23 | 2012-08-29 | エフ．ホフマン−ラ ロシュ アーゲー | アリール−イソオキサゾロ−４−イル−オキサジアゾール誘導体 |
| SG177221A1 (en) * | 2006-12-15 | 2012-01-30 | Abbott Lab | Novel oxadiazole compounds |
| GB0723814D0 (en) * | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| RU2010142655A (ru) * | 2008-03-19 | 2012-04-27 | Ауриммед Фарма, Инк. (Us) | Соединение, пригодное для лечения болезней и нарушений центральной нервной системы, и способ его получения |
| US8691824B2 (en) * | 2008-08-04 | 2014-04-08 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| RU2011123777A (ru) * | 2008-11-14 | 2012-12-20 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | Бифенилацетамидные производные |
| JP2012001537A (ja) * | 2010-05-19 | 2012-01-05 | Dainippon Sumitomo Pharma Co Ltd | ビフェニルアセトアミド誘導体からなる医薬 |
| WO2011145669A1 (ja) * | 2010-05-19 | 2011-11-24 | 大日本住友製薬株式会社 | アミド誘導体 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| PL2772482T3 (pl) | 2011-10-27 | 2016-08-31 | Taisho Pharmaceutical Co Ltd | Pochodna azolu |
| JP2013221025A (ja) * | 2012-04-19 | 2013-10-28 | Dainippon Sumitomo Pharma Co Ltd | ビフェニルアセトアミド誘導体の製造方法及びその中間体 |
| US20150299178A1 (en) * | 2012-11-12 | 2015-10-22 | Lupin Limited | Thiazole Derivatives as Alpha 7 NACHR Modulators |
| JP6387669B2 (ja) * | 2013-04-26 | 2018-09-12 | 大正製薬株式会社 | アゾール誘導体を含有する医薬 |
| WO2015161014A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| WO2017066103A1 (en) * | 2015-10-16 | 2017-04-20 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| CN108348527A (zh) * | 2015-10-30 | 2018-07-31 | Ptc医疗公司 | 用于治疗癫痫的方法 |
| DK4122923T3 (da) * | 2020-03-17 | 2025-12-15 | Sumitomo Pharma Co Ltd | Oxadiazolderivat |
-
2021
- 2021-03-16 DK DK21770862.7T patent/DK4122923T3/da active
- 2021-03-16 TW TW110109295A patent/TWI879917B/zh active
- 2021-03-16 FI FIEP21770862.7T patent/FI4122923T3/fi active
- 2021-03-16 CN CN202180036916.0A patent/CN115515943B/zh active Active
- 2021-03-16 MX MX2022011483A patent/MX2022011483A/es unknown
- 2021-03-16 EP EP21770862.7A patent/EP4122923B1/en active Active
- 2021-03-16 WO PCT/JP2021/010628 patent/WO2021187486A1/ja not_active Ceased
- 2021-03-16 KR KR1020227035750A patent/KR20220154208A/ko active Pending
- 2021-03-16 JP JP2022508381A patent/JP7637121B2/ja active Active
- 2021-03-16 ES ES21770862T patent/ES3041051T3/es active Active
- 2021-03-16 AU AU2021239631A patent/AU2021239631A1/en active Pending
- 2021-03-16 BR BR112022017530A patent/BR112022017530A2/pt unknown
- 2021-03-16 CA CA3170273A patent/CA3170273A1/en active Pending
- 2021-03-16 PT PT217708627T patent/PT4122923T/pt unknown
- 2021-03-16 US US17/905,847 patent/US20230265061A1/en active Pending
- 2021-03-16 PH PH1/2022/552373A patent/PH12022552373A1/en unknown
-
2022
- 2022-09-16 US US17/932,871 patent/US11718592B2/en active Active
-
2025
- 2025-02-14 JP JP2025022409A patent/JP2025081449A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022552373A1 (en) | 2023-12-18 |
| US11718592B2 (en) | 2023-08-08 |
| ES3041051T3 (en) | 2025-11-06 |
| EP4122923A4 (en) | 2024-04-24 |
| JP7637121B2 (ja) | 2025-02-27 |
| TWI879917B (zh) | 2025-04-11 |
| KR20220154208A (ko) | 2022-11-21 |
| EP4122923B1 (en) | 2025-09-10 |
| US20230092498A1 (en) | 2023-03-23 |
| CN115515943A (zh) | 2022-12-23 |
| FI4122923T3 (fi) | 2025-11-12 |
| US20230265061A1 (en) | 2023-08-24 |
| TW202146392A (zh) | 2021-12-16 |
| EP4122923A1 (en) | 2023-01-25 |
| AU2021239631A1 (en) | 2022-11-10 |
| WO2021187486A1 (ja) | 2021-09-23 |
| CN115515943B (zh) | 2024-07-09 |
| MX2022011483A (es) | 2022-10-07 |
| JPWO2021187486A1 (https=) | 2021-09-23 |
| CA3170273A1 (en) | 2021-09-23 |
| DK4122923T3 (da) | 2025-12-15 |
| PT4122923T (pt) | 2025-12-03 |
| AU2021239631A8 (en) | 2022-12-01 |
| JP2025081449A (ja) | 2025-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21080528A (es) | Compuestos antivirales que contienen nitrilo | |
| JOP20220131A1 (ar) | مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة | |
| JOP20200154B1 (ar) | مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات sos1 | |
| BR112021009595A2 (pt) | Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres | |
| NZ777871A (en) | Small molecule modulators of il-17 | |
| CR20190212A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| AR054234A1 (es) | Composicion farmaceutica para el tratamiento del cancer | |
| CL2021002747A1 (es) | Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020) | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| BR112012030177A2 (pt) | composto, uso do mesmo, e, composição farmacêutica | |
| PH12023550160A1 (en) | Combinations for the Treatment of Cancer | |
| NI200700064A (es) | Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3- trifluorometil-fenil)- ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos. | |
| AR066063A1 (es) | Derivados de triazol que son antagonistas de smo | |
| MX2025010357A (es) | Degradador de irak4, y uso del mismo | |
| BR112022017530A2 (pt) | Derivado de oxadiazol | |
| BR112023024311A2 (pt) | Derivado de fenil ureia | |
| MY199779A (en) | Pyrrolopyrimidine compound and use thereof | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX2024009216A (es) | Inhibidores de ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| JOP20230275A1 (ar) | معدلات trex1 | |
| MX2023014898A (es) | Terapia combinada anti-vhc ventajosa. | |
| MX2024002674A (es) | Derivados de tiadiazolona utiles como activadores de ampk. | |
| PE20231943A1 (es) | Formulacion combinada oral que incluye gemigliptina y dapagliflozina y metodo de preparacion para la misma | |
| BR112015024897A2 (pt) | derivado de fenila |